Problem

Citizen Health tackles the fragmented, exhausting work of managing rare and complex disease. Patients and caregivers often coordinate across neurologists, geneticists, therapists, hospitals, insurers, schools, and multiple electronic-record systems, leaving them to reconstruct a longitudinal medical history by hand. The burden is economically material: a U.S. study estimated the 2019 cost of 379 rare diseases at $997 billion, including $449 billion in direct medical costs, $437 billion in productivity losses, $73 billion in non-medical costs, and $38 billion in care not covered by insurance.

The killer use case is the parent or caregiver who needs to make sense of years of records before an appointment, track symptoms, handle an insurance or benefits dispute, or prepare an IEP or therapy meeting. Instead of searching hundreds of hospital documents, the caregiver can ask questions about diagnoses, medications, tests, and dates, then use the resulting summary and preparation materials to participate more effectively in care. The pain is therefore both clinical and administrative: the company is reducing the cognitive load of caregiving while helping families avoid missed information, duplicated effort, and unnecessary travel or advocacy expense.

Product / Service

Citizen Health combines a longitudinal personal health-record layer with an AI Advocate called Ari. It gathers and centralizes records from providers, lets patients and caregivers ask questions about their history, summarizes reports, prepares them for appointments, records and summarizes visits, tracks symptoms, and helps manage referrals, prior authorizations, messages, and follow-up tasks. Ari is designed to act as a persistent teammate: it remembers context across sessions, can monitor portals and flag updates, and asks for confirmation before taking consequential actions. The tools are intended to organize and explain information, not to provide medical diagnosis or treatment advice.

The delivery model is community-led and direct-to-patient. Rare-disease advocacy organizations onboard their communities, while patients access the service through the web, mobile, or text; Ari is currently in early access and free for members of partner advocacy groups, with a planned free records-and-answers tier and paid functionality in the future. The second side of the platform converts consented, de-identified longitudinal records into natural-history studies and real-world evidence, allowing patients to support research without repeated clinic visits. Citizen Health states that its revenue model is licensing aggregated, de-identified datasets to pharmaceutical companies, creating a potential research-data business alongside the free patient product.

Market

Citizen Health sits at the intersection of digital health, personal health-record aggregation, AI care navigation, rare-disease patient advocacy, and real-world evidence. Its closest alternatives are partly overlapping rather than identical: CB Insights names Datavant, Mamotest, and AllStripes among its top competitors and also lists adjacent data and record-management platforms such as PicnicHealth, OneRecord, Seqster, Epic, and Medicalchain. Citizen’s differentiation is the combination of a patient-facing AI advocate, advocacy-group distribution, and a consented research-data network focused initially on rare and complex conditions.

The company launched in December 2023 and announced a $30 million Series A in August 2025, bringing total funding to $44 million. At that point it reported more than 60 communities across 123 conditions, 70-plus advocacy-group partnerships, a 98.3% patient data-sharing rate, FDA-accepted data, and collaboration with more than 10 pharmaceutical partners. By late July 2026, a report described roughly 100 advocacy groups representing 350 rare diseases, 10,000 patient medical records on the platform, and nearly 2,000 patients and families using Ari in closed beta. The evidence establishes a well-funded, early-scale platform with a stated data-licensing model, but it does not disclose realized revenue, so its commercial maturity and revenue traction remain unproven.